Need help now? Free crisis lines and helplines, worldwide — chapter 02 →
0 results for

Metabolic Psychiatry & Brain Health — Ketogenic Therapy for Mental Illness, Epilepsy & Neurological Conditions

Category 2 of 20 in chapter 17, The Research Behind It, of Notbroken's Free Metabolic & Mental Health Help Directory: 13 listings, each carefully picked (listed, not endorsed). All 280 listings in The Research Behind It · Open the full directory of 2299 listings.
13
Listings
2 / 20
Category
17 / 18
Chapter
Latest Edition Always download the most up-to-date version, free, at notbroken.io
Know someone who could benefit? Share this guide with them.
Free to use · No account needed
Navigation
Contents
17
The Research Behind It — Free Papers on Chronic Disease and What the Evidence Shows
THE EVIDENCE
THE EVIDENCE

The Research Behind It — Free Papers on Chronic Disease and What the Evidence Shows

Why would a support group, a walking club, a low-carb book or an online CBT course help — and what drives chronic illness in the first place? This chapter gathers the research behind each part of the directory, and the research on causes: metabolic therapies, the nutrients in food, plastics and pollution, stress and trauma, the microbiome, and damp and mould. That is 280 studies, reviews and clinical guidelines, every one free to read and download in full, permanently and without a login. Most are kept in PubMed Central, the US National Library of Medicine's public archive; the rest are open access at the publisher, or free guidance from the World Health Organization and NICE. Each entry says what was found, why it matters here — which listings it backs up, or what it explains about chronic disease — and how strong the evidence is: strong (systematic reviews and guidelines with consistent findings), moderate (smaller or lower-certainty reviews, single large trials and large cohort studies) or early (pilot, cross-sectional and laboratory studies — promising, not proof). Studies that follow people over time show links, not proof of cause, and the entries say so. Where a study was funded by a company, or its authors run a listed programme, the note says so; where a listed book or service was not itself tested, the entry says it backs the approach rather than the product. Research moves on, so read these as good reasons to try something, not guarantees — and talk to your own clinician before changing a treatment or a medicine. Every paper was checked at least twice: by the researcher who chose it and again, independently, against its abstract and full text (the first 186 a third time); its public record was checked for corrections, retractions and expressions of concern (none is retracted), every number was looked up in the full text, and every link was opened in a browser.

Metabolic Psychiatry & Brain Health — Ketogenic Therapy for Mental Illness, Epilepsy & Neurological Conditions

Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group — Kossoff et al., Epilepsia Open 2018

International expert consensus guideline — 31 clinicians and dietitians (55% outside the USA), with a survey of their centres. Moderate evidence. Epilepsia Open 2018;3(2):175-192. DOI 10.1002/epi4.12225. Free full text in PubMed Central (PMC5983110) — open access, CC BY-NC-ND 4.0. Note: An expert consensus for children: many recommendations rest on clinical experience rather than trials, and it does not cover adults.
What It Found
The international guideline for ketogenic diet therapy in children, updated by 31 specialists. It says the diet should be strongly considered once two anti-seizure medicines have failed, and used first for Glut1 deficiency and pyruvate dehydrogenase deficiency. It sets out the four main diets (classic, MCT, modified Atkins, low glycaemic index), advises a trial of at least 3 months, and covers monitoring (blood tests every 3 months in the first year) and supplements.
Why It Matters Here
Backs up the epilepsy diet services and societies — the Charlie Foundation and the Global Symposium on Ketogenic Therapies in chapter 16, the International Neurological Ketogenic Society in chapter 01 and Ketogenic Diet India in chapter 14. Most relevant to parents and clinicians.
International expert consensus guideline — 31 clinicians and dietitians (55% outside the USA), with a survey of their centres. Moderate evidence. Epilepsia Open 2018;3(2):175-192. DOI 10.1002/epi4.12225. Free full text in PubMed Central (PMC5983110) — open access, CC BY-NC-ND 4.0. Note: An expert consensus for children: many recommendations rest on clinical experience rather than trials, and it does not cover adults.

Ketogenic diets for drug-resistant epilepsy — Martin-McGill et al., Cochrane Database Syst Rev 2020

Cochrane systematic review — 13 randomised or quasi-randomised trials, 932 people (711 children, 221 adults). Moderate evidence. Cochrane Database Syst Rev 2020;6:CD001903. DOI 10.1002/14651858.CD001903.pub5. Free full text in PubMed Central (PMC7387249). Note: None of the trials was blinded and certainty was rated low to very low; the benefit is clearer in children than in adults.
What It Found
Pooled trials of ketogenic diets for epilepsy that medicines had not controlled. In children (4 trials, 385 children), the diet made a 50% or greater fall in seizures nearly six times as likely as usual care (RR 5.80, 95% CI 3.48 to 9.65; low certainty) and seizure freedom about three times as likely (RR 3.16; very low certainty). In adults (modified Atkins diet, 2 trials) the effect was uncertain. Vomiting, constipation and diarrhoea were common.
Why It Matters Here
Backs up the ketogenic-therapy services for epilepsy — the Charlie Foundation and the Global Symposium on Ketogenic Therapies in chapter 16, the International Neurological Ketogenic Society in chapter 01 and Ketogenic Diet India in chapter 14. Most relevant to families of children with hard-to-treat epilepsy.
Cochrane systematic review — 13 randomised or quasi-randomised trials, 932 people (711 children, 221 adults). Moderate evidence. Cochrane Database Syst Rev 2020;6:CD001903. DOI 10.1002/14651858.CD001903.pub5. Free full text in PubMed Central (PMC7387249). Note: None of the trials was blinded and certainty was rated low to very low; the benefit is clearer in children than in adults.

Efficacy of low carbohydrate and ketogenic diets in treating mood and anxiety disorders: systematic review and implications for clinical practice — Dietch et al., BJPsych Open 2023

Systematic review — 12 studies, 389 people (9 case reports, 2 cohort studies, 1 analysis of online posts; no randomised trials). Early evidence. BJPsych Open 2023;9(3):e70. DOI 10.1192/bjo.2023.36. Free full text in PubMed Central (PMC10134254) — open access, CC BY 4.0. Note: Mostly case reports with no control groups, and ketosis was not confirmed in 5 of the 12 studies; it maps early signals, not evidence that the diet works.
What It Found
Searched for every study of low-carbohydrate or ketogenic diets in depression, anxiety, bipolar and schizoaffective disorder and found 12 (389 people), none randomised. Most reported fewer symptoms or steadier mood, mainly in bipolar and schizoaffective disorder, but two case reports found no benefit (one with worse anxiety). The authors conclude there is no high-quality evidence yet and call for robust trials.
Why It Matters Here
Backs up, with honest limits, the metabolic psychiatry listings — the books, free programme and clinician letter in chapter 10 (Brain Energy, Change Your Diet Change Your Mind, THINK+SMART), Metabolic Mind in chapter 16 and the clinician directories in chapter 01 — by setting out what is and is not yet known.
Systematic review — 12 studies, 389 people (9 case reports, 2 cohort studies, 1 analysis of online posts; no randomised trials). Early evidence. BJPsych Open 2023;9(3):e70. DOI 10.1192/bjo.2023.36. Free full text in PubMed Central (PMC10134254) — open access, CC BY 4.0. Note: Mostly case reports with no control groups, and ketosis was not confirmed in 5 of the 12 studies; it maps early signals, not evidence that the diet works.

The Ketogenic Diet for Refractory Mental Illness: A Retrospective Analysis of 31 Inpatients — Danan et al., Front Psychiatry 2022

Retrospective case series, no control group — 31 psychiatric inpatients, 28 analysed. Early evidence. Front Psychiatry 2022;13:951376. DOI 10.3389/fpsyt.2022.951376. Free full text in PubMed Central (PMC9299263) — open access, CC BY 4.0. Note: No control group or blinding, and patients were also in hospital with medicine changes; two authors had ties to low-carbohydrate companies. Randomised trials are still needed.
What It Found
Looked back at 31 adults in a French psychiatric hospital with hard-to-treat depression, bipolar II or schizoaffective disorder who were offered a ketogenic diet alongside usual care. In the 28 who kept to it for over two weeks, average depression scores (HAM-D, 23 people) fell from 25.4 to 7.7, psychosis scores (PANSS, 10 people) from 91.4 to 49.3, 43% reached clinical remission and 27 lost weight.
Why It Matters Here
Backs up the supervised approach used by Accord Metabolic Psychiatry (chapter 16) and the clinicians in the Metabolic Mind and Diagnosis Diet directories (chapter 01), as a record of ketogenic therapy in a hospital. Co-author Georgia Ede wrote the chapter 10 book and clinician letter.
Retrospective case series, no control group — 31 psychiatric inpatients, 28 analysed. Early evidence. Front Psychiatry 2022;13:951376. DOI 10.3389/fpsyt.2022.951376. Free full text in PubMed Central (PMC9299263) — open access, CC BY 4.0. Note: No control group or blinding, and patients were also in hospital with medicine changes; two authors had ties to low-carbohydrate companies. Randomised trials are still needed.

A pilot study of a ketogenic diet in bipolar disorder: clinical, metabolic and magnetic resonance spectroscopy findings — Campbell et al., BJPsych Open 2025

Single-group open pilot study — 27 adults with bipolar disorder recruited, 20 completed 6–8 weeks. Early evidence. BJPsych Open 2025;11(2):e34. DOI 10.1192/bjo.2024.841. Free full text in PubMed Central (PMC12001942) — open access, CC BY 4.0. Note: Small, uncontrolled 6–8-week study in people who were already well; the mood findings are only correlations, and the authors call for randomised trials.
What It Found
Adults with bipolar disorder who were well at the start followed a modified ketogenic diet for 6–8 weeks with weekly dietitian support; 20 of 26 who started finished. Mood scores stayed in the healthy range. On days with higher blood ketones, people rated mood and energy higher and anxiety and impulsivity lower (small correlations, 14 people). Weight fell by 4.2 kg on average and brain scans showed about 12–14% less glutamate plus glutamine in two regions.
Why It Matters Here
Backs up the bipolar listings in chapter 10 — Bipolarcast (co-host Iain Campbell was first author) and the approach in THINK+SMART, which was not itself tested — plus Metabolic Mind in chapter 16 and the metabolic psychiatry clinicians in chapter 01. For people with bipolar disorder.
Single-group open pilot study — 27 adults with bipolar disorder recruited, 20 completed 6–8 weeks. Early evidence. BJPsych Open 2025;11(2):e34. DOI 10.1192/bjo.2024.841. Free full text in PubMed Central (PMC12001942) — open access, CC BY 4.0. Note: Small, uncontrolled 6–8-week study in people who were already well; the mood findings are only correlations, and the authors call for randomised trials.

Impaired Glucose Homeostasis in First-Episode Schizophrenia: A Systematic Review and Meta-analysis — Pillinger et al., JAMA Psychiatry 2017

Systematic review and meta-analysis of case-control studies — 16 studies, 731 patients and 614 healthy controls. Moderate evidence. JAMA Psychiatry 2017;74(3):261-269. DOI 10.1001/jamapsychiatry.2016.3803. Free full text in PubMed Central (PMC6352957). Note: Shows a link, not that diet treats schizophrenia; lifestyle factors such as diet, activity and smoking could not be fully ruled out.
What It Found
Compared people at their first episode of schizophrenia, with no or at most 2 weeks of antipsychotic treatment, with healthy people. Patients already had higher fasting glucose (g 0.20), fasting insulin (g 0.41) and insulin resistance (HOMA-IR g 0.35, 95% CI 0.14 to 0.55), and these differences held in those who had never taken antipsychotics. The authors conclude that glucose regulation is altered from illness onset, not only as a side effect of medicines.
Why It Matters Here
Backs up one idea behind metabolic psychiatry — that blood-sugar regulation and insulin resistance matter in psychosis — as explained in Brain Energy and Change Your Diet, Change Your Mind (chapter 10) and by Metabolic Mind (chapter 16). Relevant to anyone weighing why metabolic health matters in psychosis.
Systematic review and meta-analysis of case-control studies — 16 studies, 731 patients and 614 healthy controls. Moderate evidence. JAMA Psychiatry 2017;74(3):261-269. DOI 10.1001/jamapsychiatry.2016.3803. Free full text in PubMed Central (PMC6352957). Note: Shows a link, not that diet treats schizophrenia; lifestyle factors such as diet, activity and smoking could not be fully ruled out.

Randomized crossover trial of a modified ketogenic diet in Alzheimer's disease — Phillips et al., Alzheimers Res Ther 2021

Randomised crossover trial (assessor-blinded) — 26 people with Alzheimer's disease, two 12-week diet periods. Early evidence. Alzheimers Res Ther 2021;13:51. DOI 10.1186/s13195-021-00783-x. Free full text in PubMed Central (PMC7901512) — open access, CC BY 4.0. Note: Small, short trial in which patients and carers knew which diet they were on; memory scores did not change significantly and LDL cholesterol rose modestly.
What It Found
26 people with Alzheimer's disease in New Zealand spent 12 weeks on a modified ketogenic diet and 12 weeks on their usual diet with low-fat healthy-eating advice, in random order; 21 completed the ketogenic phase and most reached mild ketosis. Daily function (ADCS-ADL, +3.13 points) and quality of life (QOL-AD, +3.37) were better on the ketogenic diet; the change in a memory and thinking test (ACE-III) was not significant. No serious side effects occurred.
Why It Matters Here
Backs up the ketogenic-therapy practitioners in chapter 01 for people with Alzheimer's disease; it tested a modified ketogenic diet, not the Bredesen ReCODE programme also listed there. Relevant to people with dementia and their carers (chapter 06: Alzheimer's Disease International, Dementia Alliance International).
Randomised crossover trial (assessor-blinded) — 26 people with Alzheimer's disease, two 12-week diet periods. Early evidence. Alzheimers Res Ther 2021;13:51. DOI 10.1186/s13195-021-00783-x. Free full text in PubMed Central (PMC7901512) — open access, CC BY 4.0. Note: Small, short trial in which patients and carers knew which diet they were on; memory scores did not change significantly and LDL cholesterol rose modestly.

A ketogenic drink improves cognition in mild cognitive impairment: Results of a 6-month RCT — Fortier et al., Alzheimers Dement 2021

Randomised placebo-controlled trial (BENEFIC) — 122 people with mild cognitive impairment, 83 completed 6 months and were analysed. Early evidence. Alzheimers Dement 2021;17(3):543-552. DOI 10.1002/alz.12206. Free full text in PubMed Central (PMC8048678) — open access, CC BY-NC-ND 4.0. Note: About a third dropped out (mostly stomach upsets) and only a few of many test scores improved; part-funded by Nestlé Health Science, and three authors worked for Nestlé.
What It Found
Older adults with mild cognitive impairment in Canada drank 30 g a day of a ketogenic medium-chain triglyceride (MCT) drink or a matched placebo oil for 6 months. Compared with placebo, the MCT drink raised blood ketones and improved four of many test scores (one memory measure, category fluency, naming, and errors on a mental-flexibility test); on some tests bigger ketone rises went with bigger gains. No serious side effects occurred, but stomach upsets were common.
Why It Matters Here
Backs up the idea behind ketogenic approaches to brain health offered by practitioners in chapter 01 — it tested an MCT drink, not a diet or the Bredesen ReCODE programme listed there. Relevant to people with early memory problems and the dementia organisations in chapter 06.
Randomised placebo-controlled trial (BENEFIC) — 122 people with mild cognitive impairment, 83 completed 6 months and were analysed. Early evidence. Alzheimers Dement 2021;17(3):543-552. DOI 10.1002/alz.12206. Free full text in PubMed Central (PMC8048678) — open access, CC BY-NC-ND 4.0. Note: About a third dropped out (mostly stomach upsets) and only a few of many test scores improved; part-funded by Nestlé Health Science, and three authors worked for Nestlé.

Low-fat versus ketogenic diet in Parkinson's disease: A pilot randomized controlled trial — Phillips et al., Mov Disord 2018

Pilot randomised controlled trial (assessor-blinded) — 47 people with Parkinson's disease, 38 completed 8 weeks. Early evidence. Mov Disord 2018;33(8):1306-1314. DOI 10.1002/mds.27390. Free full text in PubMed Central (PMC6175383) — open access, CC BY-NC-ND 4.0. Note: Small 8-week pilot in which patients knew their diet; 12 on the ketogenic diet had worse tremor or stiffness early on, and LDL cholesterol rose. Erratum published 2019.
What It Found
47 people with Parkinson's in New Zealand were randomised to a low-fat or a ketogenic diet for 8 weeks; 38 finished. Both groups improved. Non-motor symptoms (MDS-UPDRS Part 1) fell 41% on the ketogenic diet against 11% on the low-fat diet (between-group P<0.001), led by urinary problems, pain, fatigue, daytime sleepiness and thinking; motor scores improved on both diets, with no significant difference between them.
Why It Matters Here
Backs up the International Neurological Ketogenic Society and the ketogenic-therapy practitioners in chapter 01 for Parkinson's. Relevant to people with Parkinson's in touch with the chapter 06 organisations (Parkinson's Europe, the Michael J. Fox Foundation).
Pilot randomised controlled trial (assessor-blinded) — 47 people with Parkinson's disease, 38 completed 8 weeks. Early evidence. Mov Disord 2018;33(8):1306-1314. DOI 10.1002/mds.27390. Free full text in PubMed Central (PMC6175383) — open access, CC BY-NC-ND 4.0. Note: Small 8-week pilot in which patients knew their diet; 12 on the ketogenic diet had worse tremor or stiffness early on, and LDL cholesterol rose. Erratum published 2019.

Phase II study of ketogenic diets in relapsing multiple sclerosis: safety, tolerability and potential clinical benefits — Brenton et al., J Neurol Neurosurg Psychiatry 2022

Single-arm phase II trial — 65 adults with relapsing MS on a modified Atkins ketogenic diet for 6 months. Early evidence. J Neurol Neurosurg Psychiatry 2022;93(6):637-644. DOI 10.1136/jnnp-2022-329074. Free full text in PubMed Central (PMC9350909). Note: No control group and mostly self-reported outcomes; the authors say it was not designed to show the diet works, which needs a randomised trial.
What It Found
65 adults with stable relapsing MS followed a modified Atkins ketogenic diet for 6 months; 83% kept to it, checked with daily urine ketone strips. Fatigue (MFIS) fell by about 14 points and depression (BDI) by about 4, quality-of-life scores rose by 11–12 points, the 6-minute walk improved by 78 feet and fat mass fell by 7.7 kg. Constipation and diarrhoea were the commonest side effects; no relapses were reported.
Why It Matters Here
Backs up the ketogenic-therapy practitioners and societies in chapter 01 and Ketogenic Diet India in chapter 14, which covers MS. It tested a modified Atkins ketogenic diet, not the Wahls Protocol or Overcoming MS (a low-saturated-fat diet). For people with relapsing MS.
Single-arm phase II trial — 65 adults with relapsing MS on a modified Atkins ketogenic diet for 6 months. Early evidence. J Neurol Neurosurg Psychiatry 2022;93(6):637-644. DOI 10.1136/jnnp-2022-329074. Free full text in PubMed Central (PMC9350909). Note: No control group and mostly self-reported outcomes; the authors say it was not designed to show the diet works, which needs a randomised trial.

Impact of the Swank and Wahls elimination dietary interventions on fatigue and quality of life in relapsing-remitting multiple sclerosis: The WAVES randomized parallel-arm clinical trial — Wahls et al., Mult Scler J Exp Transl Clin 2021

Randomised parallel-group trial (assessor-blinded) — 87 adults with relapsing-remitting MS and fatigue, Wahls vs Swank diet for 24 weeks. Early evidence. Mult Scler J Exp Transl Clin 2021;7(3):20552173211035399. DOI 10.1177/20552173211035399. Free full text in PubMed Central (PMC8326636) — open access, CC BY-NC 4.0. Note: No usual-diet comparison group, participants knew their diet, and the lead author created the Wahls diet and has financial interests in it.
What It Found
87 people with relapsing-remitting MS and fatigue were randomised to the Wahls elimination diet or the low-saturated-fat Swank diet for 24 weeks, after a 12-week usual-diet run-in. Fatigue (FSS) fell on both diets, with no significant difference between them. The Wahls group had larger gains in quality of life, and only the Wahls group's 6-minute walk improved significantly at 24 weeks (+36.6 m).
Why It Matters Here
Backs up the Wahls Protocol listings — the practitioner directory in chapter 01 and the book in chapter 10 — as a randomised test of one version of the Wahls diet, and Overcoming MS in chapter 16, whose diet, like the Swank diet tested here, is low in saturated fat.
Randomised parallel-group trial (assessor-blinded) — 87 adults with relapsing-remitting MS and fatigue, Wahls vs Swank diet for 24 weeks. Early evidence. Mult Scler J Exp Transl Clin 2021;7(3):20552173211035399. DOI 10.1177/20552173211035399. Free full text in PubMed Central (PMC8326636) — open access, CC BY-NC 4.0. Note: No usual-diet comparison group, participants knew their diet, and the lead author created the Wahls diet and has financial interests in it.

Ketosis and migraine: a systematic review of the literature and meta-analysis — Neri et al., Front Nutr 2023

Systematic review and meta-analysis — 10 studies (3 small randomised crossover trials, 7 non-randomised). Early evidence. Front Nutr 2023;10:1204700. DOI 10.3389/fnut.2023.1204700. Free full text in PubMed Central (PMC10292926) — open access, CC BY 4.0. Note: Few, small, mostly non-randomised studies, most from one Italian research group, with high heterogeneity and inconsistent checks of ketosis.
What It Found
Reviewed 10 studies of ketogenic diets or ketone supplements for migraine (one on cluster headache), mostly in Italian adults (16–96 people each). In the studies that reported it, 58–83% of people had at least 50% fewer attacks, but of the three randomised crossover trials only one (a very-low-calorie ketogenic diet) found fewer attacks; the other two found no clear benefit.
Why It Matters Here
Backs up, cautiously, the ketogenic-therapy practitioners and the International Neurological Ketogenic Society in chapter 01 for migraine. Relevant to people with migraine, including those using the National Headache Foundation in chapter 06, but the evidence is still thin.
Systematic review and meta-analysis — 10 studies (3 small randomised crossover trials, 7 non-randomised). Early evidence. Front Nutr 2023;10:1204700. DOI 10.3389/fnut.2023.1204700. Free full text in PubMed Central (PMC10292926) — open access, CC BY 4.0. Note: Few, small, mostly non-randomised studies, most from one Italian research group, with high heterogeneity and inconsistent checks of ketosis.

International recommendations for the management of adults treated with ketogenic diet therapies — Cervenka et al., Neurol Clin Pract 2021

International expert recommendations — survey of 20 centres treating more than 2,000 adults, plus the medical literature. Early evidence. Neurol Clin Pract 2021;11(5):385–397. DOI 10.1212/CPJ.0000000000001007. Free full text in PubMed Central (PMC8610544). Note: Preliminary recommendations from a survey and expert opinion, not from randomised trials; centres differed on monitoring and long-term safety checks.
What It Found
Neurologists and dietitians from 20 centres that had treated more than 2,000 adults with ketogenic diet therapies compared their practice and the literature to set preliminary recommendations for adults: who may benefit, how to start, what side effects to expect and how to monitor them. They conclude these diets may be safe and effective for adults with drug-resistant epilepsy, with emerging evidence in other neurological conditions.
Why It Matters Here
Backs up the metabolic and ketogenic practitioners in chapter 01: it shows why medically supervised ketogenic therapy, with monitoring, matters for adults with epilepsy or other neurological conditions.
International expert recommendations — survey of 20 centres treating more than 2,000 adults, plus the medical literature. Early evidence. Neurol Clin Pract 2021;11(5):385–397. DOI 10.1212/CPJ.0000000000001007. Free full text in PubMed Central (PMC8610544). Note: Preliminary recommendations from a survey and expert opinion, not from randomised trials; centres differed on monitoring and long-term safety checks.
Important Disclaimer
This directory is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making changes to your medication regimen or starting any new therapy.

This document does not guarantee the legitimacy, quality, or suitability of any business, organization, or practitioner listed within. The inclusion of any listing does not constitute an endorsement, recommendation, or verification of credentials. All organizations listed are independent entities over which the creators of this directory have no control or oversight.

This directory is intended to be used as a starting point and reference for the reader to conduct their own research, exercise their own judgment, and apply their own discretion before engaging with any listed organization or professional. Readers are strongly encouraged to independently verify credentials, read reviews, check licensing, and confirm current pricing and availability directly with each organization before committing to any services.

Costs, availability, contact details, and services may change at any time without notice. Information was accurate to the best of our knowledge at the time of publication.

About Notbroken.io: this directory and the accompanying Breathe, Calm, Sleep, Move, Eat, Track and Build tools were created by Nathan Leary, who runs and updates them. How each tool works, its safety notes, the privacy policy and terms of use are at notbroken.io/about, notbroken.io/privacy and notbroken.io/terms. The tools are general wellness aids, not medical devices, and Track is a personal journal that never gives medication advice.

If you are in crisis: Please contact your local emergency services immediately, or reach out to one of the following helplines:

International: Chapter 02 of this directory lists free helplines by situation and country; elsewhere use Find A Helpline — findahelpline.com
United States: 988 Suicide & Crisis Lifeline (call or text 988) • Crisis Text Line (text HOME to 741741)
United Kingdom: Samaritans — 116 123 (free, 24/7)
Canada: Talk Suicide Canada — 988 (call or text, 24/7)
Australia: Lifeline — 13 11 14 (24/7) • Beyond Blue — 1300 22 4636
New Zealand: Need to Talk? — 1737 (free, 24/7)
Europe: European Emergency Number — 112
India: iCall — 9152987821 • Vandrevala Foundation — 1860 2662 345
Singapore: Samaritans of Singapore — 1-767 (24/7)
Japan: TELL Lifeline — 03-5774-0992

No matches found

Nothing matched . Try broadening your search — remove a filter, use a single keyword, describe what you need in a sentence, or browse by a condition, a place, or a type of support.

Suggest a resource